Background: Lung cancer is the leading cancer diagnosis worldwide and the number 2
commensal microbes. Evidence of this has been demonstrated in patients with cystic 1 fibrosis who have more virulent forms of P. aeruginosa [9] . These inflammatory 2 associated events have been proposed to lead to an increased risk or progression of 3 diseases, including lung cancer. 4
Several bacteria are associated with chronic inflammation and subsequent increased risk 5 of lung and colon cancer, including Mycobacterium tuberculosis (lung cancer) [10] 6
Bacteroides fragilis and Fusobacterium nucleatum (colon cancer) [11] . Recent 7 microbiome studies in colon cancer have demonstrated a contribution of bacteria to 8 carcinogenesis. Specifically, F. nucleatum, a bacterium commonly isolated from patients 9
with inflammatory bowel disease, may be a risk factor for colon cancer [11, 12] . The more 10 virulent strains of F. nucleatum affect colon cancer progression in animal models and 11 increase tumor multiplicity [13] by various mechanisms including favoring the infiltration 12 of tumor-promoting myeloid cells to create a pro-inflammatory environment [14] . 13
Colorectal carcinomas associated with high abundance of fecal F. nucleatum were found 14 to have the highest number of somatic mutations, suggesting that these mutations create 15 a pathogen-friendly environment [15] . Similarly, B. fragilis can secrete endotoxins that 16 cause DNA damage leading to mutations and colon cancer initiation [16] . Furthermore, 17 the loss of the oncogenic protein p53 in enterocytes impairs the epithelial barrier and 18 allows infiltration of bacteria resulting in inflammatory signaling (NF-κB), which is required 19 for tumor progression [17] . The tumor suppressor gene TP53 is the most commonly 20 mutated gene in lung cancer [18] , with certain missense mutations showing gain of 21 oncogenic function [19] ; however, the relationship between TP53 and microbiota in lung 22 cancer remains unknown. Herein, we hypothesize that somatic mutations together with 23
Though we had reduced power, we asked whether the time since quitting smoking would 1 change this association, and found that Acidovorax, Klebsiella, Tepidimonas, 2 Rhodoferax, and Anaerococcus remained significant. When we examined the larger 3 TCGA data set, we also found significantly increased odds of being SCC as compared 4 with AD among 4/9 (Acidovorax, Klebsiella, Rhodoferax, Anaerococcus) of the same 5 genera in adjusted models (FDR corrected P<0.05) ( Figure 2D and see Additional file 1: 6 Table 6 ). This association also remained significant after adjusting for pack years and 7 time since quitting smoking. Together these data, validated in two separate cohorts, 8 demonstrate that a specific community of taxa is more abundant in SCC as compared 9
with AD lung cancer tissue, and are capable of distinguishing between AD and SCC 10 tumors from individuals with similar exposure to cigarette smoke. However, whether this 11 is a cause or consequence of the development of SCC cancer remains unknown. 12 Both SCC and AD lung cancers are associated with smoking, however, the association 13 between smoking and SCC is stronger [30] , which lead us to ask whether any of the SCC-14 enriched taxa were also associated with smoking. We stratified the tumor samples into 15 never smokers (n=7) or ever-smokers (current (n=70) and former smokers (n=40)) using 16 linear discriminant analysis (LEfSe) to identify smoking-associated microbial biomarkers 17 in SCC tumors. We identified 6 genera that were able to distinguish ever (former and 18 current) vs non-smokers in our NCI-MD study (Acidovorax, Ruminococcus, Oscillospira, 19 Duganella, Ensifer, Rhizobium) (see Additional file 1: Figure S4C ). Specifically, 20
Acidovorax was more abundant in former and current smokers as compared with never 21 smokers (Kruskal-Wallis p-value <0.05) ( Figure 3A) , with a similar trend observed in 22 TCGA data set (n never =120, n former =551, n current =217) (Kruskal-Wallis P=0.27; ANOVA 23 P=0.02). We did not, however, observe any correlation between Acidovorax abundance 1 and smoking time cessation. Interestingly, the relative abundance of Acidovorax and 2 Klebsiella were higher in former and current smokers when we stratified by histological 3 subtype in both NCI-MD and TCGA data set ( Figure 3B , see Additional file 1: Figure S5 ), 4
indicating not only are there bacteria which have a higher relative abundance in tumors 5 from individuals who smoke, but SCC tumors from smokers have even greater relative 6 abundance of these bacteria. We also demonstrated the presence of this bacterium in 7 lung tumors using FISH ( Figure 3C -D and see Additional file 1: Figure S6 ), and using 8
PacBio sequencing, which identified the species as A. temperans (see Additional file 1: 9 Table 4 ). We did not find any significant associations between pack years or time since 10 quitting smoking and the abundance of these taxa in either study among SCC tumors in 11 either study. 12 TP53 mutations are associated with enrichment of SSC enriched taxa. The most 13 prevalent somatic mutation in SCC lung tumors is in the gene TP53 [31] . Previous studies 14 demonstrate that mutations in TP53, specifically in colon cancer, lead to disruption of the 15 epithelial barrier allowing the infiltration of tumor-foraging bacteria and resulting in disease 16 progression [17] . Given that TP53 mutations are found in 75-80% of SCC tumors, we 17 hypothesized that these SCC-associated taxa may be more abundant in tumors with 18 TP53 mutations, owing to the loss of the epithelial barrier function in these tumors. To 19 address this question, we investigated the association between TP53 mutations in both 20 NCI-MD (n=107) and TCGA (n=409) data sets using either TP53 specific sequencing 21 (MiSeq) or the published TP53 mutation analysis data from TCGA [31] . We first analyzed 22 all tumors in the NCI-MD study regardless of histology and identified a group of taxa that 23 were more abundant in tumors with TP53 mutations ( Figure 4A ). To have greater power, 1 we performed the same analysis in the TCGA data set and observed a significant increase 2 in these same taxa (MW FDR corrected P<0.05) ( Figure 4B ). When analyzing only SCC 3 tumors (n=46), this signature became stronger in tumors with TP53 mutations in both data 4 sets, specifically among the SCC-associated taxa previously identified ( Figure 4C-D) . In 5 the NCI-MD study we found that 5/9 of the genera (Acidovorax, Klebsiella, Rhodoferax, 6
Comamonas, and Polarmonas) that differentiated SCC from AD were also more abundant 7 in the tumors harboring TP53 mutations, though not statistically significant ( Figure 4C) . 8
In the TCGA data set, the fold change in all 5 SCC-associated genera were significantly 9 higher in SCC tumors (n=177) with TP53 mutations (MW corrected FDR <0.01; Figure  10 4D). Furthermore, using these same SCC-associated taxa we observed no pattern of 11 association in AD tumors with TP53 mutations indicating this signature was specific to 12 SCC with TP53 mutations (see Additional file 1: Figure S7A -B). Overall, these data are 13 consistent with the hypothesis that mutations in TP53 are associated with the enrichment 14 of a microbial consortia that are highly represented in SCC tumors. 15
Conclusions: 16
Gene-environment interactions have been identified as contributors to cancer incidence 17
[32] , however little is known about gene-microbiome interactions in carcinogenesis. We 18 demonstrate, a gene-microbiome association in human lung cancer, as well as, 19 histological evidence of a smoking-associated bacterium, Acidovorax. Herein, we identify 20 a microbial consortia that is associated with a histological subtype of lung cancer, SCC, 21 which is further enriched in tumors with mutations in TP53. Given the strong association 22 between smoking and development of SCC, it follows that a subgroup of this SCC 23 consortium would also be found in smoking-associated SCC. We validate this assumption 1 finding Acidovorax spp. more abundant in SCC tumors harboring TP53 mutations, and 2 confirmed the presence of this genus histologically. These results suggest that smoking 3 may provide an environment conducive to the growth of Acidovorax spp. and similar 4 species, which can flourish in nutrient depleted environments, like that of the lung. More 5 important these bacteria are capable of using and degrading environmental toxicants, like 6 those found in tobacco smoke [33] . Alteration of the microenvironment could allow these 7 species to become tumor-foraging bacteria once the epithelial barrier defense is lost as 8 a consequence of mutations in TP53 and malignant transformation. The counterfactual is 9 also possible. In other words, overgrowth of Acidovorax spp., as the result of smoking 10 and epithelial barrier damage, may induce mutations by activation of carcinogens, and 11 propagation of mutated epithelial cells. Whether these species are simply opportunists or 12 contribute to lung cancer progression, should be the subject of future investigations. 13
Collectively, these observations indicate that a state of dysbiosis exists in lung cancer. 14 The hypothesis generated is that epithelial cells in the lung exposed to tobacco smoke 15 and/or mutations in TP53 are invaded by species that take advantage of this new 16 microenvironment. Notably, individuals harboring mutations in TP53 with stage I SCC 17 also have poorer prognosis [34] , thus it will be important to determine if any of the species 18 enriched in SCC are functionally related to reduced survival or simply biomarkers of a 19 diminished mucosal barrier function. Future studies could test the hypothesis using germ-20 free mouse models of lung cancer inoculated with SCC-associated spp. prior to or after 21 lung tumors are present. 22
Our study indicates that smoking is associated with alterations in relative abundance of 1 species in SCC tumors. The number one risk factor for lung cancer is tobacco exposure 2 and is a known factor in chronic lung inflammation. Tobacco and cigarette smoke contain 3 bacterial products (i.e. LPS) that can cause inflammation, impaired barrier function and 4 potentially alter the microbiome to influence lung carcinogenesis [8, 35, 36] . Additionally, 5 tobacco leaves harbor both mold and potentially pathogenic bacteria that can be 6 transferred in a viable form into the respiratory tract on tobacco flakes inhaled in 7 mainstream smoke [35, 36] . Further, biologically significant quantities of bacteria are 8 microaspirated daily in healthy individuals [37] , and thus is possible for these species to 9 accumulate in a pathogen-friendly environment. Given that Acidovorax spp. ,which have 10 been identified in 2 common brands of cigarettes [38] , have the capacity to metabolize 11 multiple organic pollutants, like those found in cigarette smoke, it is plausible that smoking 12 creates an environment that allows this bacterium to outcompete other species for 13 resources and thus survival [39] . Further, these bacteria are capable of metabolizing 14 polycyclic aromatic hydrocarbons, which are tobacco smoke carcinogens that can cause 15 DNA adducts, suggesting they may actually contribute to lung carcinogenesis. 16
Oral and nasal microbiome differences have been observed between smokers and non-17 smokers [40, 41] . Whether smoking alters the lung tissue microbiome; however, is still 18 not well understood, especially in the context of disease. From a large study of the naso-19 and oropharynx, significant differences in microbial communities were identified between 20 smokers and non-smokers [42] . Additionally, in a study of non-malignant lung tissue 21 (n=152), they observed a significant increase in alpha diversity with higher number of 22 pack years of smoking [43] . While they identified Acidovorax, Anaerococcus and 23 Comamonas in smokers, these taxa did not differentiate smokers and non-smokers in a 1 healthy population. However, in a recent study of non-malignant lung tissue, which 2 compared tissue to isolated extracellular vesicles (EVs) from tissues, the greater diversity 3 was identified specifically in EVs, with a greater abundance of Acidovorax specifically 4 found in the EVs of smokers, indicating a possible factor in differential findings [44] . These 5 data indicate that smoking alone may be insufficient to alter the microbial population in a 6 healthy population. However, smoking has been shown to suppress the immune system 7 and induce epithelial barrier dysfunction [45] . These factors may allow taxa direct access 8 to epithelial cells where microbial toxins or reactive oxygen/nitrogen from the 9 aforementioned species to directly or indirectly encourage malignant transformation of 10 the lung epithelium via DNA damage and mutations in TP53 [46] [47] [48] nucleatum were found to have the highest number of somatic mutations, suggesting that 22 these mutations create a pathogen-friendly environment [11, 15] . Furthermore, the loss 23 of p53 in enterocytes impairs the epithelial barrier and allows infiltration of bacteria 1 resulting in NF-κB signaling, which was required for tumor progression [17] . This evidence 2 suggests that SCC tumors with TP53 mutations could have poor epithelial barrier 3 function, thus allowing tumor foraging bacteria, like those identified in our study, to 4 become more abundant in tumors with TP53 mutations. The counterfactual is also 5 possible. Similar to the B. fragilis toxin ETBF, which is genotoxic and initiates colon 6 carcinogenesis in animal models [52] , one or more of the tumor-associated species may 7 induce TP53 mutations. Whether any of these bacteria are promoting SCC tumorigenesis 8 or inducing mutations in TP53 is currently under investigation. 9
With the majority of lung cancer being diagnosed at late stage, the recent advancement 10 in the treatment of late stage (III/IV) lung cancer with immune checkpoint inhibitors 11 targeting PD-1, nivolumab, has resulted in a 40% reduced risk of death as compared to 12 standard chemotherapy [53] . The response rate, however, is still not complete for these 13 patients. Important insights into understanding the differential response rates of this new 14 immunotherapy has suggested the composition of the lung microbiome prior to therapy 15 as a key player in therapeutic effectiveness [54] . Given our results demonstrating 16 alterations in the microbial composition in lung cancer that are histology and mutation 17 specific, future studies should address whether the lung or nasal microbiome composition 18 improves the stratification of patients who would be most responsive to immunotherapy. 19
This suggestion is supported by recent animal studies demonstrating the contribution of 20 the gut microbiome to the effectiveness of immunotherapy [55] . 21
The strength of our findings include the large number of individuals sampled in this study, 22
use of two separate sample populations, two sets of control populations, two separate 23 sequencing methodologies (MiSeq and PacBio) and microscopic validation (FISH) of the 1 species in lung tumor tissue. We have also been diligent in assessing the possibility of 2 contaminating taxa being an artifact of sample collection or sample processing by 3 sequencing across 2 different platforms, and microscopy, although we cannot rule that 4 possibility out entirely. While we were able to control for antibiotic exposure in the NCI-5 MD study, we acknowledge a limitation of the validation study is the inability to control for 6 antibiotic exposure in the TCGA dataset, as well as, significant differences in clinical 7 features between the cancer cases and controls, which could be confounders. However, 8 in a recent study of the microbiome of endoscopic gastric biopsies, confirmation of 9 multiple shared bacteria in clinical samples, specifically H. pylori, was demonstrated using 10 the TCGA RNA-seq data with methods similar to those presented in our study [56] . 11
With these results, we foresee a new avenue for mechanistic studies to address the role 12 of microbe-host relationship in lung cancer inflammation, response to therapy, and 13 microbial engineering for drug delivery. 14
Methods: 15
Sample Populations and data sets: Samples used for DNA extraction, PCR and 16 sequencing were obtained from the ongoing NCI-MD study (7 hospitals participating in 17 the greater Baltimore, MD area recruited from 1999 to 2012), as described 18 previously [57], from which 398 lung cancer cases were obtained, and included both 19 tumor and non-tumor adjacent, with 121 matched pairs. The final sample set used for 20 analysis after sequencing, which contained 106 matched pairs after quality control, is 21
found in See Additional file 1: Table 1 . Lung tumors and paired non-tumor adjacent 22
samples from the NCI-MD study were obtained at the time of surgery, from which 23 a section of tumor and non-involved adjacent lung tissue were flash frozen and 1 stored at -80 degrees. At the time of study entry, a detailed patient interview was 2 conducted to obtain basic clinical information in addition to previous cancers, neo-3 adjuvant therapies, current medications, family history of cancer, smoking history, 4 education level and financial status. Staging was assigned using the Cancer Staging 5
Manual of the American Joint Committee on Cancer (AJCC) 7th edition. Pre-operative 6 antibiotics were administered for those cases recruited after 2008 and any antibiotic oral 7 medication use was used as a co-variate for all statistical analysis in model testing, 8 however these data were not available for immediate autopsy (ImA) non-cancer 9 samples. Controls representing non-cancerous tissue were obtained from the Lung 10
Cancer Biorepository Research Network (n=16; hospital controls). Theses samples were 11 obtained as frozen lung specimens from individuals who had a previous positive nodule 12 identified by PET scan, and subsequently underwent tissue biopsy, which was ruled 13 benign. Clinical information included those listed above as well as smoking history, 14 antibiotic usage (Y/N), and disease diagnosis. Two cases had emphysema at the time of 15 biopsy and were not used in the analyses. Immediate autopsy (ImA) samples obtained 16 from the University of Maryland (UMD) hospital, which is part of the NCI-MD study 17 population (n=41; population controls) (See Additional file 1: Table 1 ). Lung tissue from 18
ImA was received frozen from the UMD biorepository and served as the population 19 controls for non-cancer lung tissue. Briefly, samples from ImA were obtained within 20 minutes (<30 min.) after death and put on ice for dissection or frozen to -80 degrees. All 21
ImA subjects underwent extensive autopsy and were determined to be cancer free. 22
Demographic information included age, gender, race and cause of death only. Non-23 smokers in the NCI-MD study were categorized as having smoked <100 cigarettes or 1 fewer than 5 packs over a lifetime, whereas smokers were categorized as current 2 smokers or formers smokers, which had quit for > 6 months. Sequences derived from 3 RNA-seq of lung tumor (n=1006) or non-tumor adjacent tissue (n=106) were obtained 4 from The Cancer Genome Atlas (N=1112) for validation of the NCI-MD study16S rRNA 5 gene sequencing analysis and results. Due to the fact that all RNA-seq data in TCGA 6 were obtained using poly-A capture, any microbial data from this analysis will necessarily 7 be biased. For this reason, we only used these data as validation of results first identified 8 in our 16S rRNA gene sequencing analysis. Public data, including all clinical patient 9 information (See Additional file 1: Table 1 ), was downloaded from the Data Matrix on the 10 TCGA website, https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm. The raw data 11 in the form of BAM and FastQ files were download from a secure server at CGHUB, and 12 access was applied for and approved for raw data downloads by University of California pathology and sequencing were also collected through routine swabs after surgery and 4 sequenced in conjunction with tissue samples. Specifically, the NCI-MD study tissues 5
were isolated in a laminar flow hood to minimize contamination for downstream 6 applications, using sterile forceps and gloves. Controls for contamination points during 7 surgical tissue collection and pathological assessment included swabs from inside of the 8 surgical tissue collection vessel before/after, pathology cutting board before/after, 9 pathology knife blade before/after, gloves before/after, pathology ink bottle rim and 10 collection tube for freezing before/after (See Additional file 1: Dataset 1). Briefly, swabs 11
were dipped in Yeast cell Lysis buffer and area/object swabbed, then the swab was 12 broken off into tube and frozen at -80. A negative control was also collected using 50 μL 13 of MoBio PCR water as a mock sample (PCR_NC) and processed through DNA 14 extraction with tissues to assess contamination from reagents, which was analyzed on 15 three separate runs of MiSeq. The positive control was the High Even Mock Community 16 (Broad Institute), which was also sequenced on three separate runs of MiSeq. The 17 negative and positive control samples were spiked into four MiSeq runs at a similar 18 concentration to that of the NCI-MD samples. To control for false grouping or batch 19 affects, we randomized the tissue sample types (non-tumor (NT), tumor (T), immediate 20 autopsy (ImA)) (with the exception of HB controls) across 5 separate sequencing runs of 21
MiSeq (See Additional file 1: Dataset 2). The fifth plate consisted of duplicate samples 22 and samples that had failed sequencing on previous runs of MiSeq. 23
Sequencing for the 16S rRNA gene was performed with 40 ng of sample DNA from 398 1 cases and 57 controls using primers for variable region V3-V5 with 16S rRNA gene 2 sequence-specific portions based on Kozich et al. [58] with adapters for subsequent 3 addition of standard Illumina dual indexes. PCR was performed using a Phusion DNA 4
Polymerase High Fidelity kit (ThermoFisher). The cycling conditions were as follows: 98 5 °C for 2 min, then 36 cycles of 98 °C for 15 s, 60 °C for 1 min 40 s, and 74 °C for 1 min. 6 PCR products were purified using the Agencourt AMPure XP kit according to the 7 manufacturer's instructions (Beckman Coulter). Second round PCR with Illumina dual-8 index oligos was performed using a Phusion DNA Polymerase High Fidelity kit 9 (ThermoFisher) as following: 98 °C for 2 min, then 6 cycles of 98 °C for 15 s, 72 °C for 20 10 s, and 72 °C for 1 min. Samples were pooled, purified using Agencourt AMPure XP. 11
Sequencing was conducted on Illumina MiSeq instrument using v3 600 cycles kit (see 12
Additional file 1: Methods). water. Cleaned PCR products were quantified using the Bio-Rad QX200 droplet digital 21 PCR (Bio-Rad) and QX200 EvaGreen® Supermix with primers F357 and R534 (see 22
Additional file 1: V1 on the normalized pooled PCR products. Sequencing was performed using the PacBio 6 RS II platform using protocol "Procedure & Checklist -2 kb Template Preparation and 7
Sequencing" (part number 001-143-835-06). DNA Polymerase Binding Kit P6 V2 was 8 used for sequencing primer annealing and polymerase binding. SMRTbell libraries were 9 loaded onto SMRTcells V3 at a final concentration of 0.0125 nM using the MagBead kit, 10 as determined using the PacBio Binding Calculator software. Internal Control Complex 11 P6 was used for all reactions to monitor sequencing performance. DNA Sequencing 12
Reagent V4 was used for sequencing on the PacBio RS II instrument, which included 13
MagBead loading and stage start. Movie time was 3 hrs for all SMRTcells. PacBio 14 sequencing runs were set up using RS Remote PacBio software and monitored using 15 RS Dashboard software. Sequencing performance and basic statistics were collected 16 using SMRT® Analysis Server v2.3.0. De-multiplexing and conversion to FastQ was 17 accomplished using the Reads of Insert (ROI) protocol in the SMRT portal v2.3 software. 18
Only reads with a minimum of 5 circular passes and a predicted accuracy of 90 (PacBio 19 score) or better were used for further analysis. Each read was labelled in the header with 20 the number of CCS (circular consensus sequence) passes and the sample designation 21 using a custom ruby script, followed by concatenation of all reads into a single file for 22 subsequent filtering and clustering. 23
Filtering and OTU clustering of 16S rRNA gene sequence data: Initial screening for 1 length and quality using QIIME (qiime.org) [59] . Reads containing more than five 2 consecutive low quality base calls (Phred < Q20), were truncated at the beginning of the 3 low quality region. Due to the low quality of the majority of R2 reads (Phred < Q20 and 4 <150bp length), we used the R1 reads only for this analysis. Passing sequences were 5 required to have high quality base calls (≥ Phred Q20) along a minimum of 75% of the 6 read length to be included. After primer removal, final sequences containing ambiguous 7 bases (Ns) or lengths less than 150bp were removed. High quality sequences were then 8 screened for spurious PhiX contaminant using BLASTN with a word size of 16. Reads 9
were then assessed for chimeras using USEARCH61 (de novo mode, 97% identity 10 threshold for clustering). Non-chimeric sequences were screened for contaminant 11 chloroplast and mitochondria using the RDP naïve Bayesian classifier, as well as non-12 specific human genome contaminant using Bowtie2 against the UCSC hg19 reference 13 sequence. Finally, sequences were evaluated for residual contaminants using BLASTN 14 searches of the GreenGenes database (v13.5). Filtered reads included those not 15 matching any reference with at least 70% identity along 60% of their length. Exploratory 16 assessment using BLASTN searches against the NCBI NT database indicated the 17 majority unknown contaminant reads were amplified human genome sequence. High-18 quality passing sequences were subsequently clustered into operational taxonomic units 19 using the open-reference operational taxonomic unit (OTU) picking methodology 20 implemented within QIIME using default parameters and the GreenGenes database (99% 21
OTUs) supplemented by reference sequences from the SILVA database (v111). Prior to 22 downstream diversity analyses, the OTU table was rarefied to 5,500 sequences per 23 sample. Prior to diversity analysis, contaminants were removed and again OTUs table 1 rarified to 5,500 sequences per sample. Alpha diversity estimators and beta-diversity 2 metrics were computed in QIIME with differential abundance analyses performed in R. In 3 order to determine significant differences in beta diversity, we used the adonis function in unmapped reads from TCGA lung cancer samples, we developed a custom metagenomic 10 analysis pipeline using (i) MetaPhlAn2, (ii) Kraken, and (iii) Pathoscope [22] . First, all 11 reads were filtered for quality using Trimmomatic (v0.32, minimum average quality > 12 20 over a 5bp sliding window, minimum final length ³ 28bp) and searched for potential 13 PhiX-174 contaminant using Bowtie2. Reads passing this filter were then mapped to 14 the comprehensive NCBI Homo sapiens Annotation (Release 106) using Bowtie2 15 to remove any human-associated reads. The resulting non-human read set was 16 then taxonomically assigned using (i) MetaPhlAn2, (ii) Kraken, and (iii) Pathoscope in 17 parallel to evaluate consistency in the resulting profiles. Assignments from each 18 method were aggregated at higher taxonomic levels (genus and species) for 19 downstream statistical comparisons. The results from Pathoscope and its validation 20 in other studies lead us to use these data for the remainder of the downstream analysis. 21
Alpha diversity estimators and beta-diversity (Bray Curtis) metrics were computed in 1 QIIME using genus and species level assignments with differential abundance analyses 2 performed in R and Stata (v13). and beta-diversity metrics were computed in QIIME with differential abundance analyses 5 performed in R and Stata (v13). Mann-Whitney tests corrected for multiple testing 6 (Benjamini-Hochberg (FDR)) were used to conduct initial comparisons between tissue 7 type and histological subtype (AD or SCC) followed by multivariable logistic regression 8 controlling for multiple confounders. A logistic regression model was constructed to 9 estimate the odds of AD vs SCC for each taxa stratified by mutation status with and 10 interaction term between the taxa and mutation added to the model. See See Additional 11 file 1: Methods for details. 12 TP53 gene sequencing and mutation analysis: Genomic DNA extracted from lung 13 cancer tissues (n=107) was submitted for TP53-targeted sequencing using the MiSeq 14 Illumina platform. For mutation analysis, 46 samples were SCC. The assay was targeted 15 at the exons and proximal splice sites. Forward and reverse primers were tailed with 16 Illumina Adapter tags for downstream next generation sequencing using the BioMark HD 17 System (Fluidigm) and Access Array IFC chips and kits (Fluidigm). PCR products were 18 indexed using an 8-mer oligo barcode. See Additional file 1: Table 3 lists sequences for 19 primers used in the sequencing assay. Sequence results were processed and aligned to 20 human genome and underwent QC requiring coverage > 100 reads with the variant (most 21
SNVs had a read depth in the thousands) and minimum allele frequency > 10%. The 100-22 level cutoff for coverage allows to detect variations if the tumor fraction >~ 20% with 95% 23 confidence, under the assumption of a diploid genome. The 10% allele frequency cutoff 1 is derived from that same consideration. The variants called included all common 2 polymorphisms. Because only tumor was sequenced, in order to score somatic mutations, 3 those deemed to be germline were filtered out. These included SNVs present in dbSNP 4 with high reported allele frequency (common polymorphisms). Also, SNVs in untranslated 5 regions and introns were not considered, as their somatic status and functional 6 implications are unclear. The presence of putative somatic exonic and splicing variants 7 was corroborated in TCGA and COSMIC datasets. See Additional file 1: Table 2 for 8
details. 9
Fluorescent in situ hybridization analysis of Acidovorax: In order to confirm the 10 presence Acidovorax in lung tumor tissue, fluorescently labeled probes were created for 11 each bacterium. Genus or species-specific bacteria probes were hybridized using tumor 12 tissues in addition to gram stain on each. Tumor tissues from cancer cases were fixed in 13 OCT and sectioned frozen (10 μm). Prior to fixation in 4% paraformaldehyde sections 14 were thawed at RT. Sections were washed in PBS and the probe (2 μL) was added to 90 15 μL FISH buffer (0.9 M NaCl, 0.02 M Tris pH 7.5, 0.01% SDS, 20% formamide). This 16 solution was added to the section (20-100 μL) and placed in the hybridization chamber 17 (46°C) for 3-18 hrs depending on probe used. Section were washed with twice (wash 1 18 -0.9 M NaCl, 0.02 M Tris pH 7.5, 0.01% SDS, 20% formamide; wash 2 -0.9 M NaCl, 19 0.02 M Tris pH 7.5, 0.01% SDS) and incubated at 48°C for 15 min. Slides were then dried 20 for 10 min. Prior to visualization, DAPI and Vectashield was added slides. The probe used 21 for FISH was: Acidovorax (CTT TCG CTC CGT TAT CCC, 5' modification: Alexa Fluor 22 532). Representative fields were imaged using Zeiss 710 and a 100X objective for the 23 probe. In addition to 2D images, Z stacks were also obtained for each bacterial probe and 1 used to reconstruct 3D images and movies using Imaris software. Quantification of 2 Acidovorax probe reactivity was conducted using 10 2D fields of two patients. At least 3 300 cells were counted per patient. Percentage (%) of cells with perinuclear probe 4 reactivity was quantified using ImagePro Plus 6.0 software. 5
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